PreMD Announces Positive Data On Life Insurance Product
Life Insurance Product
Analysis on PreMD's PREVU(x) LT test shows the product as a cost-effective and valuable cardiovascular risk assessment tool for the life insurance industry.
PREVU(x)LT is the second product in the PREVU(x) line of skin cholesterol tests and has been developed for use within the life insurance industry.
"Based on the initial analysis, PREVU(x) LT appears to provide significant value as a non-invasive marker for evaluating cardiovascular disease risk for life insurance applicants," said Brent Norton, president and chief executive officer of PreMD. "We expect that the relevance of this information on PREVU(x) LT will demonstrate the market potential for this test in the life insurance industry. We are also excited about the commercialization prospects for this product and are discussing the PREVU(x) LT test with insurance providers this week at the AHOU conference in Toronto."
Recent data shows that PREVU(x) LT could help determine which individuals could be classified as Preferred Risk for cardiovascular disease. This data is based on information from the PREPARE (PREVU(x) Predicts Atherosclerosis Risk and Events) study, conducted in the insurance industry with the participation of selected U.S. life insurers. It has also been shown that in females with low PREVU(x) LT results, significantly fewer had total cholesterol (TC):high density lipoprotein (HDL) ratio of greater than 5. Analysis of this data shows that life insurance companies could yield substantial savings when issuing policies to these applicants. Final analysis is expected in the upcoming weeks.